| Description |
1 online resource (xiv, 155 pages) : illustrations |
| Contents |
Preface; Foreword; Contents; TNF -- tumour necrosis factor [alpha]; Mode of action of anti-TNF; TNF-blocking drugs in clinical use; TNF-blocking drugs not in clinical use; Section 1 TNF-blocker safety; Increased risk of infection; Tuberculosis; Opportunistic infections; Injection-site reactions; Allergic, hypersensitivity reactions, anaphylactic responses; Psoriasis; Infusion reactions (infliximab); Malignancy and lymphoproliferative conditions; Drug-induced lupus-like reactions; Anti-drug antibodies (immunogenicity); Congestive heart failure; Neurological; Hepatobiliary; Use in pregnancy; Lactation |
|
RespiratoryVaccinations; Use of TNF-blockers with other medications; Haematological; Postmarketing safety experience in Crohn's disease; Section 2 Rheumatology; Rheumatoid arthritis; Other rheumatological conditions; TNF-blocking therapy in ankylosing spondylitis and psoriatic arthritis; Ankylosing spondylitis; Psoriatic arthritis; Adalimumab (Humira); Etanercept (Enbrel); Infliximab (Remicade); Certolizumab pegol (Cimzia); Abatacept (Orencia); Anakinra (Kineret); B-cell depletion: Rituximab (Rituxan® [USA], MabThera® [Europe, Asia, South America]); Section 3 Dermatology; Psoriasis |
|
Approaches to managementAssessing disease severity; Important differences between psoriasis and rheumatoid arthritis; Biological therapy for psoriasis; Etanercept (Enbrel); Infliximab (Remicade); Adalimumab (Humira); Efalizumab (Raptiva); Alefacept (Amevive); Section 4 Gastroenterology; Biological therapy in inflammatory bowel disease and Crohn's disease; Adalimumab (Humira); Infliximab (Remicade); Natalizumab (Tysabri); Certolizumab pegol (Cimzia); Index; A; B; C; D; E; G; H; I; K; L; M; N; O; P; R; S; T; U; V |
| Summary |
Drugs produced by molecular biological techniques, called the 'biologics', differ from the usual chemical medications. Their optimum use, and the detection and managemenet of adverse events, pose a significant challenge to the clinician. Licences for new biologics continue to be granted for the likes of rituximab, abatacept and certocizumals pegol. Intensive research is also defining new areas in which these drugs will be used in the future, increasing the number of practitionersusing biologics. As the use of these drugs increases around the world, so the level of information needed by primary |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002. http://purl.oclc.org/DLF/benchrepro0212 MiAaHDL |
|
English |
|
Print version record |
|
digitized 2010 HathiTrust Digital Library committed to preserve pda MiAaHDL |
| Subject |
Biological products -- Therapeutic use.
|
|
Tumor necrosis factor -- Inhibitors
|
|
Tumor Necrosis Factor-alpha -- therapeutic use
|
|
Gastrointestinal Diseases -- therapy
|
|
Rheumatic Diseases -- therapy
|
|
Skin Diseases -- therapy
|
|
Biological Therapy
|
|
MEDICAL -- Pharmacology.
|
|
Biological products -- Therapeutic use
|
| Form |
Electronic book
|
| Author |
Kirkham, Bruce.
|
| LC no. |
2009277297 |
| ISBN |
9780191548970 |
|
0191548979 |
|
9780191768583 |
|
0191768588 |
|
1283581272 |
|
9781283581271 |
|
9786613893727 |
|
6613893722 |
|
